Abstract
‘Severe Acute Respiratory Syndrome - Coronavirus-2’ (SARS-CoV-2) infection causes Coronavirus Disease 2019 (COVID-19), a mild to moderate respiratory tract infection in the majority of patients. A subset of patients, however, progresses to severe disease and respiratory failure with acute respiratory distress syndrome (ARDS). Severe COVID-19 has been associated with increased neutrophil counts and dysregulated immune responses. The mechanisms of protective immunity in mild forms and the pathogenesis of dysregulated inflammation in severe courses of COVID-19 remain largely unclear. Here, we combined two single-cell RNA-sequencing technologies and single-cell proteomics in whole blood and peripheral blood mononuclear cells (PBMC) to determine changes in immune cell composition and activation in two independent dual-center patient cohorts (n=46+n=54 COVID-19 samples), each with mild and severe cases of COVID-19. We observed a specific increase of HLA-DRhiCD11chi inflammatory monocytes that displayed a strong interferon (IFN)-stimulated gene signature in patients with mild COVID-19, which was absent in severe disease. Instead, we found evidence of emergency myelopoiesis, marked by the occurrence of immunosuppressive pre-neutrophils and immature neutrophils and populations of dysfunctional and suppressive mature neutrophils, as well as suppressive HLA-DRto monocytes in severe COVID-19. Our study provides detailed insights into systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the peripheral myeloid cell compartment associated with severe courses of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the German Research Foundation (DFG, SFB-TR84 #114933180 to L.E.S., S.H., A.H., N.S., C.D.; INST 37/1049-1, INST 216/981-1, INST 257/605-1, INST 269/768-1 and INST 217/988-1, INST 217/577-1 to J.L.S; SFB TR57, SPP1937 to J.N.; GRK2157 to A.-E.S., ME 3644/5-1 to H.E.M.); the Berlin University Alliance (BUA, PreEP-Corona grant to L.E.S., V.C. and C.D.), the Berlin Institute of Health (BIH, grant to L.E.S., A.H., C.D.); the HGF grant sparse2big, the EU projects SYSCID (grant number 733100), and ERA CVD (grant number 00160389) to J.L.S.; the DZIF (TTU 04.816, 04.817 to J.N.); the Hector-Foundation (M89 to J.N.); the EU projects ONE STUDY (grant number 260687 to B.S.), BIO-DrIM (305147 to B.S.) and INsTRuCT (grant number 860003 to B.S.), the German Federal Ministry of Education and Research (BMBF, project RAPID to C.D., S.H., A.H.), and a Charite 3R project to B.S. and S.H.; Radboud University Medical Centre Hypatia Grant (2018 to Y.L.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review board of Charité (EA2/066/20)and the Institutional Review board of the University Hospital Bonn (073/19 and 134/20).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are deposited at the European Genome-phenome Archive (EGA) under access number EGAS00001004450, which is hosted by the EBI and the CRG.
